Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
13.01
+0.32 (2.52%)
Oct 7, 2025, 3:15 PM EDT - Market open
Amylyx Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts that cover Amylyx Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $15.14, which forecasts a 16.37% increase in the stock price over the next year. The lowest target is $8.00 and the highest is $25.
Price Target: $15.14 (+16.37%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Amylyx Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 3 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 7 | 8 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $14 → $16 | Strong Buy | Maintains | $14 → $16 | +22.98% | Oct 3, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $10 → $20 | Strong Buy | Maintains | $10 → $20 | +53.73% | Sep 16, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $17 → $25 | Strong Buy | Maintains | $17 → $25 | +92.16% | Sep 15, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $10 → $14 | Strong Buy | Maintains | $10 → $14 | +7.61% | Aug 28, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | -23.14% | Jul 10, 2025 |
Financial Forecast
Revenue This Year
n/a
from 87.37M
Revenue Next Year
93.98K
EPS This Year
-1.81
from -4.43
EPS Next Year
-1.55
from -1.81
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 677,250 | |||
| Avg | n/a | 93,983 | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.52 | -0.85 | |||
| Avg | -1.81 | -1.55 | |||
| Low | -1.98 | -1.93 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.